The purpose of this study is to determine the efficacy and safety of a
buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for
M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the
study and sign informed consent.
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant
and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.
Acute hepatitis. Other medical condtions that deem participation to be unsafe.